Studies have shown that 90% of cancer patients have hemostatic disorders, shortened prothrombin and partial thromboplastin time, and increased factors II, V, VIII, IX, XI, and XII, fibrinogen, and fibrin degradation products [14]. The gene discussed is F2; the disease is cancer.